Journal
Journal issues
Editorial Advisory Board
Aims & Scope
Spotlights
Webinars
Fast Facts
Media Kit
Media kit
Editorial Calendar
Webinars
About
Get in touch
Meet the Team
Submit your manuscript
Cell and Gene Therapy Insights
Login
Register
Update your profile
Logout
IMMUNO-ONCOLOGY
INSIGHTS
Search
Latest Spotlight
Previous Spotlights
Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics – April 2022
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
K Hagerbrand,
P Ellmark
The end of an era of cancer drug discovery: life without new drug targets
A Mardiros,
A Kamb
Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?
E Patz
Forging new paths in immuno-oncology
R McGuigan,
M Tuna
Promise & challenges in discovering cellular immunotherapies &T cell engagers for solid tumor indications
P Sivakumar
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?
N Wang
View all
Optimizing clinical development strategy for the rapidly evolving I-O field
1 March 2022
Dissecting investor and market access trends and drivers for I-O R&D insights
1 February 2022
Anticipating immuno-oncology modality/platform development trends for 2022
26 January 2022
Bioprocessing/CMC trends, tools and techniques
1 November 2021
Leveraging cutting edge tools to convert I-O data into knowledge
1 September 2021
Enhancing preclinical predictivity
1 July 2021
View all
Upcoming webinars
On Demand Webinars
Life on a chip - vascularized micro-tumor chips for mimicking clinical...
C Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
20
Days
23
Hrs
36
Min
Register
Overcoming current challenges in immunotherapy drug development with...
S F. Boj
Sylvia F. Boj
Chief Scientific Officer at Hubrecht Institute
15 Jun 2022
27
Days
23
Hrs
36
Min
Register
Thinking translational: Things to consider in CAR T cell research workflows
S Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
34
Days
23
Hrs
36
Min
Register
Accelerating cell therapy discovery & development with non-viral gene...
D Hermanson
X Patrinostro
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
7
Hrs
36
Min
Register
Monitoring of circulating CAR T cells
A Graband,
D Hünecke,
D Bremm
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
12
Days
23
Hrs
36
Min
Register
View all
Enabling clinical grade manufacturing of gene-engineered NK cells
N Möker,
E Ullrich,
R Romee
et al.
Nina Möker
R&D Reagents Manager, Allogeneic Cell Therapy, Miltenyi Biotec
Prof. Dr. Evelyn Ullrich
Arbeitsgruppe Zelluläre Immunologie, Universitätsklinikum, Frankfurt am Main (kgu.de)
Rizwan Romee, MD
Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
Volker Huppert
Chief Development Officer Glycostem Therapeutics
30 November 2021
Watch now
Advancing engineered cell and gene therapy with precision gene editing
D Maddalo
Danilo Maddalo
Group Leader, Translational Oncology, Genentech
11 November 2021
Watch now
Gain deeper insights into the mechanisms of immune cell killing of tumor cells:...
C Souders,
T Dale,
N Bevan
et al.
Dr Colby Souders
Chief Scientific Officer, Abveris
Tim Dale, PhD
Head of BioAnalytics Applications, Sartorius
Nicola Bevan
Manager of Cell Imaging Applications, Sartorius
Jeffrey Skolnik, M.D.
Senior Vice President, Clinical Development, Inovio
6 October 2021
Watch now
The therapeutic gene editing solution – cell therapy for solid tumors
B Sasu,
P Sivakumar,
J Trager
et al.
Barbra Sasu, PhD
Chief Scientific Officer, Allogene Therapeutics
Pallavur Sivakumar, PhD
Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
James Trager, PhD
Chief Scientific Officer, Nkarta Therapeutics
Jennifer Harbottle, PhD
Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
30 September 2021
Watch now
Get your non-viral T cell engineering process ready for clinical manufacturing
M Rietenbach,
S Wild,
K Patel
Melanie Rietenbach
Global Product Manager Miltenyi Biotec
Stefan Wild
Senior Manager, Research and Development, Miltenyi Biotec
Kunal Patel
Process Engineering Manager, Miltenyi Biotec
21 September 2021
Watch now
Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...
N Ph.D.,
R Fan,
T Laskowski, Ph.D.
Nina Senutovitch Ph.D.
Senior Scientist, Product Development, Cell Imaging, Sartorius
Professor Rong Fan
Professor of Biomedical Engineering, Yale University
Tamara J. Laskowski, Ph.D.
Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
5 August 2021
Watch now
View all
Latest content
A winning combination in the war against deadly cancers: exploring new...
R Dixit
Rakesh Dixit
President & CEO, Bionavigen, Gaithersburg, MD, USA and President and CSO, Regio Biosciences, Rockville, MD, USA
25 April 2022
Commentary
Update on antibody–drug conjugates: where are we now, & where are we...
F Arnaldez
Fernanda Arnaldez
Executive Global Product Leader – Early Development Oncology Research and Development AstraZeneca
18 April 2022
Viewpoint
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment...
K Hagerbrand
P Ellmark
Karin Hägerbrand
Alligator Bioscience, Medicon Village, Lund, Sweden
Peter Ellmark
Alligator Bioscience, Medicon Village, Lund, Sweden Dept. Immunotechnology, Lund University, Sweden
11 April 2022
Expert Insight
The end of an era of cancer drug discovery: life without new drug targets
A Mardiros
A Kamb
Armen Mardiros
Director, Translational Science, A2 Biotherapeutics , Inc.
Alexander Kamb
Chief Scientific Officer A2 Biotherapeutics , Inc.
11 April 2022
Viewpoint
Driving disruption in the solid tumor space: is it time to shift paradigms...
E Patz
Edward Patz
Chief Executive Officer, Grid Therapeutics, LLC and James and Alice Chen Distinguished Professor of Radiology, Professor in Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
8 April 2022
Interview
Forging new paths in immuno-oncology
R McGuigan
M Tuna
Roisin McGuigan
Editor Immuno-Oncology Insights
Mihriban Tuna
Chief Scientific Officer, Adaptate Biotherapeutics
6 April 2022
Foreword
Spotlight on optimizing clinical development strategy
J O'Donnell-Tormey
Jill O'Donnell-Tormey
Chief Executive Officer & Director - Scientific Affairs at Cancer Research Institute
29 March 2022
Foreword
Cancer immunotherapy & clinical trial design: issues & practice
J Dancey
Janet E Dancey, MD, FRCPC
Canadian Cancer Trials Group Cancer Research Institute Queen’s University Kingston, Ontario, Canada
29 March 2022
Commentary
Expediting drug development & targeting early-stage disease: how is...
P Forde
Patrick Forde
Director Thoracic Oncology Clinical Research Program Associate Professor of Oncology Johns Hopkins
27 March 2022
Interview
View all
×
Please enter your email to register
Register